Abstract:Background and objective Nowadays, comprehensive treatment, including surgery, chemotherapy and radiotherapy is advocated for stage III non-small cell lung cancer (NSCLC). However, many researchers have questioned the effectiveness of surgery. The aim of this study is to evaluate the effect of surgery for stage III NSCLC. Methods Between March 2002 and October 2012, 310 cases that have completed followed-up data with stage III NSCLC were received in the Peking Union Medical College Hospital. They were divided into surgical and non-surgical groups according to whether received surgery when diagnosed. In TNM staging, stage III NSCLC includes stage IIIa and IIIb, and stage IIIa NSCLC can be grouped into stage T4N0/T3-4N1M0 and T1-3N2M0 according to different N stages. Analyzed the enumeration data by Chi-Square test. Kaplan-Meier survival method was used to calculate the overall survival (OS) and progression-free survival (PFS), and to draw the survival curves. A P value less than 0.05 was evaluated as statistically significant. Results Three hundred and ten stage III NSCLC patients include surgical group 189 cases and non-surgical group 121 cases. One hundred and eighty-eight stage IIIa NSCLC patients include surgical group 152 cases and non-surgical group 36 cases. In stage IIIa, stage T4N0/T3-4N1M0 had 57 patients with 44 surgical and 13 non-surgical patients, and stage T1-3N2M0 had 131 patients with 108 surgical and 23 non-surgical patients. Thirty-seven out of 121 stage IIIb NSCLC patients received surgery. They had 22 stage T4N2M0 cases and 15 stage T1-4N3M0 cases. The patient whose performance status was 0 and staging was stage IIIa was more inclined to undergo surgery. For stage IIIa NSCLC patients, the median OS of surgical and non-surgical groups were 38.9 and 21.8 months, and the median PFS of them were 19.2 and 11.9 months respectively. The difference of OS between the two groups was significant (P=0.041), but the PFS of them had no significant difference (P=0.209). For stage T4N0/T3-4N1M0 which belongs to stage IIIa, the median OS of surgical and non-surgical groups were 48.7 and 20.1 months, and the median PFS of them were 14.6 and 10.5 months respectively. There were no significant differences of OS and PFS between the two groups (P>0.05). For stage T1-3N2M0 which also belongs to stage IIIa, the median OS of surgical and non-surgical groups were 38.9 and 30.8 months, and the median PFS of them were 19.8 and 12.7 months respectively. There were also no significant differences of OS and PFS between the two groups (P>0.05). The maximum diameter of tumor and auxillary chemotherapy had significant influences on OS and PFS of stage IIIa-N2 NSCLC patients, while the histology of tumor only influenced the OS of them (P<0.05). Conclusion The patient whose performance status is 0 and staging is stage IIIa is more inclined to undergo surgery. Surgery can prolong OS of patients with stage IIIa, especially for stage T4N0/T3-4N1M0. However, it has no benefit on PFS. The maximum diameter of tumor and auxillary chemotherapy have significant influences on OS and PFS of stage IIIa-N2 NSCLC patients, while the histology of tumor only influence the OS of them.

[Survival Benefit of Primary Site Surgery Acquired by Stage Ⅳ Non-Small Cell Lung Cancer: a Retrospective Study Based on Seer Database].

The consideration of surgery on primary lesion of advanced non-small cell lung cancer

Improved survival of patients with stage III small-cell lung cancer with primary resection: A SEER-based analysis

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Propensity Score Matched Analysis for the Role of Surgery in Stage Ⅲ Small Cell Lung Cancer Based on the Eighth Edition of the TNM Classification: a Population Study of the US SEER Database and a Chinese Hospital.

Surgical Intervention May Be a Therapeutic Option for NSCLC Patients with AJCC Stage IV: a Large Population-Based Study.

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Retrospective study on surgery and post-operative adjuvant treatment in stage Ⅲa non-small cell lung cancer

Value of Surgery for Stage IIIa Non-small Cell Lung Cancer

Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation

Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis

Propensity Score Matching Analysis for the Role of Surgery in Small Cell Lung Cancer.

[Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients Treated with Surgery].

Primary tumour resection in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): a population-based study.

Resection of Early-Stage Second Primary Non-small Cell Lung Cancer after Small Cell Lung Cancer: A Population-Based Study

Lobectomy Can Improve the Survival of Patients with Non-small Cell Lung Cancer with Lung Oligometastatic

Survival Value of Primary Tumour Resection for Stage IV Non-Small-cell Lung Cancer: A Population-Based Study of 6466 Patients

Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database

Effects of Surgery on Survival of Early-Stage Patients with SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database.

Choice of Treatment for Patients with Non–small-cell Lung Cancer >5 Cm Between Surgery Alone and Surgery Plus Adjuvant Radiotherapy

P1.17-18 Treatment for Patients with T4 Superior Sulcus Non-Small Cell Lung Cancer: A Propensity-Matched Analysis of SEER Database